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Abstract 
Consistent evidence associates IGF‑1 deficiency and metabolic syndrome. In this review, we will focus on the meta‑
bolic effects of IGF‑1, the concept of metabolic syndrome and its clinical manifestations (impaired lipid profile, insulin 
resistance, increased glucose levels, obesity, and cardiovascular disease), discussing whether IGF‑1 replacement 
therapy could be a beneficial strategy for these patients. The search plan was made in Medline for Pubmed with 
the following mesh terms: IGF‑1 and “metabolism, carbohydrate, lipids, proteins, amino acids, metabolic syndrome, 
cardiovascular disease, diabetes” between the years 1963–2015. The search includes animal and human protocols. 
In this review we discuss the relevant actions of IGF‑1 on metabolism and the implication of IGF‑1 deficiency in the 
establishment of metabolic syndrome. Multiple studies (in vitro and in vivo) demonstrate the association between 
IGF‑1 deficit and deregulated lipid metabolism, cardiovascular disease, diabetes, and an altered metabolic profile of 
diabetic patients. Based on the available data we propose IGF‑1 as a key hormone in the pathophysiology of meta‑
bolic syndrome; due to its implications in the metabolism of carbohydrates and lipids. Previous data demonstrates 
how IGF‑1 can be an effective option in the treatment of this worldwide increasing condition. It has to distinguished 
that the replacement therapy should be only undertaken to restore the physiological levels, never to exceed physi‑
ological ranges.
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Mitochondrial dysfunction, Cellular protection
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Background
Consistent data from multiple studies (in vitro and 
in  vivo) demonstrate the association between IGF-1 
deficit and deregulated lipid metabolism, cardiovascular 
disease (CVD), diabetes, and altered metabolic profile 
of diabetic patients. On the other hand, metabolic syn-
drome (MetS) is a constellation of symptoms that implies 
a higher risk for CVD and type 2 diabetes (T2D), increas-
ing the morbidity and mortality of these patients. As it 
is a syndrome clustering different features, the common 
causative aetiology is yet unknown. Nevertheless, the 
insulin resistance and abdominal adiposity seems to be 
essential in the pathophysiological process, and for this 
reason, based on the information available, we propose 
IGF-1 as a key hormone in the pathophysiology of meta-
bolic syndrome due to its implications in the metabo-
lism of carbohydrates and lipids. Accumulated evidence 
shows that IGF-1 can be an effective option in the treat-
ment of this prevalence-increasing condition, as we shall 
further explain in detail.
Therefore, in this review our aim is to bring all IGF-1 
information regarding metabolism together with the 
objective of offering clear insight into the issue—this way 
clarifying how miss-regulation of the GH/IGF-1/insulin 
axis can lead to metabolic disorders such as MetS and 
diabetes; introducing how obesity and insulin resistance 
(initiating factors for the onset of MetS and diabetes) 
may be opposed by recombinant-human-IGF-1 (rhIGF-
1) treatment. Firstly, the concept of metabolic syndrome 
and its different definitions will be reviewed, together 
with the symptoms or risk factors associated. Secondly, 
IGF-1’s molecular structure and known actions with 
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in detail. To continue, IGF-1 and IGF-1 binding proteins 
will be linked to parameters of metabolic syndrome, dia-
betes, insulin resistance, and obesity. Lastly, IGF-1 will 
be proposed as valid optional treatment for patients with 
MetS in which diet and exercise failed due to genetic 
traits.
Metabolic syndrome
For many decades, the concept of “clustering” metabolic 
disorder and CVD risk factors has been widely discussed. 
Table  1 summarises historical definitions and evolu-
tion of MetS diagnosis. However, the term “Metabolic 
Syndrome” has become commonly used since its incep-
tion by the “Executive Summary of the Third Report of 
the National Cholesterol Education Program” (NCEP) in 
2001 [1]. Since then, many different concepts and defini-
tions have been proposed. Hence, it was not until 2009 
when a harmonised definition was finally described 
[2]. According to this definition, a diagnosis of MetS 
is made when 3 of the following 5 risk factors are pre-
sent: enlarged waist circumference with population and 
country-specific criteria; elevated triglycerides (defined 
as  ≥150  mg/dL), decreased High Density Lipopro-
tein (HDL) (ranges below 40 mg/dL in men and 50 mg/
dL in women), elevated blood pressure (defined as sys-
tolic blood pressure above 130 mmHg or diastolic blood 
pressure above 85  mmHg) and elevated fasting glucose 
(defined as blood glucose above 100 mg/dL). This defini-
tion includes those patients that are taking medication 
to manage hypertriglyceridemia, low HDL, hypertension 
and hyperglycemia [2].
In general MetS continues to be a clustering of symp-
toms that seem to play a major role as CVD and T2D 
risk factors, raising the necessity of encouraging these 
patients to pursue lifestyle changes. Moreover, the har-
monised definition criteria was found to be a better pre-
dictor of CVD than each of its separate components or 
the Framinghan Score—this was not applicable for T2D 
[3].
The prevalence of MetS is difficult to establish since it 
depends on the definition [1, 2, 4–6] and the composi-
tion of the population being studied [7–29]. To dissolve 
this issue different studies have been undertaken in order 
to estimate the prevalence of MetS. Nowadays we can 
understand that sex, age, race and ethnicity, in the con-
text of socioeconomic status and lifestyle (tobacco, alco-
hol, education, physical exercise, unbalanced diet, etc.) 
impacts directly in its prevalence [7, 8, 10, 27– 36]. Fur-
thermore, it is well known that it is increasing worldwide 
[37], this is thought to be related to the westernisation of 
lifestyle habits [38, 39].
It is well known that MetS represents an assortment 
of factors that increase the risk of CVD [11] and T2D 
by different means [11, 40–55]. Obesity and insulin 
resistance are associated with endothelial dysfunction, 
sympathetic nervous system hyperactivity, and hyper-
leptinaemia, all of which can lead to hypertension. Fur-
thermore, insulin resistance can lead to abnormal lipid 
profiles, like low-HDL and high triglyceride (TG) levels. 
These two factors can increase the risk for CVD [56–60], 
nonetheless there is some controversy about the role of 
TG levels in the CVD development [57]. In summary, 
the majority of the studies have found that patients with 
MetS are at increased risk for developing CVD [11, 37, 
39–55]. Additionally, as previously mentioned, a recent 
study has described that MetS -taking the harmonised 
definition criteria for diagnosis—is a better predictor for 
CVD than the sum of each of its separate components or 
the Framingham Score. Other studies have found that the 
more components of the MetS are present, the greater 
the risk of developing CVD [42, 53, 61].
Moreover, MetS is also a good predictor for the devel-
opment of T2D [62–64]. Insulin resistance, hyper-
insulinemia, dyslipidaemia, and obesity precede the 
progression to T2D in 75–85 % of patients [65], and the 
presence of MetS increases up to fivefold the risk for T2D 
compared to individuals without MetS [66, 67]. This risk 
is increased up to 6-7-fold, if insulin resistance is present 
[54].
Other conditions that have been associated with MetS 
are strongly related with insulin resistance and adipos-
ity, namely, non-alcoholic fatty liver disease (NAFLD), 
polycystic ovarian syndrome, obstructive sleep apnoea 
(OSA), hypogonadism, lipodystrophy, and microvascu-
lar disease. Moreover, the presence of NAFLD is a robust 
predictor of MetS [68]. Liver fat also correlates to each 
of the components of MetS [69]. In the case of OSA, 
there is evidence—adjusting for obesity—that individuals 
with this alteration are more likely to develop MetS than 
those without OSA [70–72]. Also, sleep disorders have 
been associated with weight gain and insulin resistance 
[73–77]. In the case of microvascular disease, some stud-
ies relate it to MetS, independent to the presence of T2D 
[78–86], but further studies are needed to ensure these 
results.
Insulin‑like growth factor‑1
Insulin-like growth factor 1 (IGF-1) is a 70-aminoacid 
polypeptide hormone with endocrine, paracrine, and 
autocrine effects, which shares structural homology 
(>60 %) with IGF-2 and proinsulin [87, 88]. It is mainly 
produced by the liver (accounting for  ≈75  % of circu-
lating IGF-1) secondary to growth hormone (GH) and 
insulin endocrine stimulation in the liver. Conversely, 
IGF-1 acts to provide an inhibitory feedback signal 
on GH secretion in the hypothalamus by stimulating 
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somatostatin production in the pituitary [89–91]. IGF-1 
is also produced locally in all bodily tissues [92]. IGF-1 
availability is tightly regulated by the so-called insulin-
like growth factor binding proteins (IGFBPs), which may 
act by increasing IGF-1 half-life, from minutes to hours 
(most commonly by forming a tertiary complex with 
Acid-Labile Subunit and IGFBP3), however blocking its 
binding to the insulin-like growth factor 1 receptor (IGF-
1R) [93–95]. IGFBPs can also act to guide IGF-1 to spe-
cific tissues, or even to inhibit or potentiate IGF-1 actions 
by acting as an independent substrate for the IGF-1R 
and/or other specific membrane, intracellular or nuclear 
receptors [93–95]. To date there have been described 
6 high affinity IGFBPs [93–95]. Moreover, insulin-like 
growth factor binding protein related proteins (IGFB-
PrPs) have been recently characterised, which aid the 
metabolic effects of the hormone but their role remains 
unclear [96, 97]. Relevant roles of each specific IGFBPs 
will be further discussed when applicable to metabolism 
since there is a huge emerging world of IGFBPs inde-
pendent actions.
IGF-1 can act over its putative receptor (IGF-1R) or it 
can also bind to the insulin receptor (IR), albeit with less 
affinity [98–100]. In addition, there is a hybrid receptor 
with components of the IR (one α and one β-chain) and 
the IGF-1R (one α and one β-chain), to which both insu-
lin and IGF-1 can bind to, but with less affinity than that 
of their putative receptors [98–100]. All of these recep-
tors have tyrosine kinase activity, hence are natural and 
potent activators of the Akt pathway [98–100].
IGF-2 actions have been poorly characterised, however 
relevant roles have been determined for foetus develop-
ment and cerebral protection [101, 102]. IGF-2 can act 
over its own receptor (IGF-2 receptor—IGF-2R), which 
is a manose-6-phosphate transmembrane protein with 
undetermined actions—it is thought that it acts as a scav-
enger receptor by sequestering IGF-2 and IGF-1 from the 
extracellular medium and targeting them for destruction 
[103]. Nonetheless, it seems that it could have intracellu-
lar targets instead of only being proteolysed. As of recent 
discovery IGF-2R shows to activate Gαq proteins within 
cardiomyocites [104]. Additionally, IGF-2 can also act 
over IGF-1R, IR and hybrid receptors but with reduced 
affinity [103].
In the last decades, IGF-1 has been implicated in many 
physiological actions, among others: tissue growth and 
development, proliferative, lipid metabolism, pro-sur-
vival/anti-aging, anti-inflammatory, anabolic, and anti-
oxidant with neuro- and hepatoprotective properties 
[105–116]. IGF-1 exerts protective effects over mito-
chondria by preserving it from the oxidative damage gen-
erated by augmented metabolism, and increasing ATP 
synthesis and reducing intramitochondrial production of 
free radicals [105–107].
Insulin receptor, insulin‑like growth factor‑1 receptor 
and insulin resistance signalling
As a brief review of insulin signalling and its resistance 
molecular basis: insulin and IGF-1 receptors (IR and 
IGF-1R) are tyrosine kinases. As such they attract mol-
ecules containing a Src-homolgy 2 (SH2) domain (several 
docking sites for phosphorylated tyrosines). The most 
often and potent ones attracted are the insulin receptor 
substrates 1/2 (IRS1/2)—although there are 6 found to 
date- (not to forget that Shc proteins, p60dok, Cbl, APS, 
and Gab-1 are also recruited to activated IRs). These pro-
vide additional tyrosine residues to be phosphorylated by 
the tyrosine kinase domain of the activated receptor that 
will attract further molecules containing SH2 domains 
or plekstrin homoly (PH) domains, these last will anchor 
IRS to phosphoinositides on the cell membrane. When 
PI3K and its regulatory proteins, p85 and p110, are 
recruited by IRS, they will further recruit and activate 
PDK1 (PIP3-dependent kinase 1), Akt (PKB), mTORC2, 
S6 kinases and PKC; all leading to augmented glucose 
transport, glycogen and protein synthesis. Zick and col-
leagues [117] have elegantly summarised recent evidence 
that show how IRS also possess serine residues that can 
be phosphorylated. When this happens tyrosine phos-
phorylation becomes less likely to happen. This is, in a 
certain way, a termination pathway to uncouple the insu-
lin signalling. There are other mechanisms to terminate 
the insulin signalling that include lipid and protein phos-
phatases along the cascade and controlling mechanisms; 
long-term regulation includes transcription inhibition 
of the IR and proteolysis by ubiquitination. One conver-
gent pathway activated by IGF-1R and IR is the mTORC1 
and mTORC2 signalling. It is widely known they both 
posses serine and threonine phosphorylation capability. 
However, it has been recently described that mTORC2 
also possesses tyrosine phosphorylation capacity [118], 
and that it phosphorylates tyrosines on IRS and tyrosine 
kinases in both receptors, IGF-1 and IR, thus reinstitut-
ing the signal of the activated receptors [118]. Whilst 
mTORC1 activates S6 kinase, which phosphorylates ser-
ine residues on IRS which in turn uncouples IRS from the 
receptor and its substrates, mTORC2 can reactivate this 
signalling.
Complementary to the above, it has been thought for a 
long time that only supraphysiological concentrations of 
IGF-1 are able to activate the IR, as will be further dis-
cussed in this manuscript. However, the exact mecha-
nism by which IGF-1 improves insulin signalling has not 
yet be explained (other than indirect actions through 
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lipid clearance from the bloodstream by inhibiting GH 
(lipolysis on adipocytes) and FFA uptake by muscles; all 
these mechanisms are collected below). We now propose 
a feasible mechanism: Denley and colleagues [119] have 
beautifully designed a study where they demonstrate 
how IR has a splice variant lacking exon 11 which con-
fers the receptor affinity for IGF-1 and IGF-2. In this way, 
IGF-1 gains the ability to stimulate the IR, and without 
activating the tyrosine kinase domain, recruits IRS-2. 
Complementarily, IGF-1R preferentially activates IRS-2 
[120] as it was found that IRS-2 contains a KLRB domain 
that functions to block the tyrosine kinase domain in 
the cytoplasmic region of the IR, and that such does 
not happen in the IGF-1R. Thus suggesting a specificity 
for IGF-1R. It has been found, using specific knock out 
(KO) mice and cultures, different specific activities for 
IRS-1 and IRS-2, additional further complexity comes 
with tissue-specific roles. For example, in muscle, IRS-1 
is more related to glucose uptake whereas IRS-2 stimu-
lates the MAPK pathway [121]. In the liver, they both 
have metabolic regulation actions, but IRS-2 has a more 
profound role in lipid metabolism [121]. Additional com-
plexity, and in accordance with IGF-1 secretion patterns, 
appeared when researchers found that IRS-1 was found 
more active in post-prandial states contrary to IRS-2 
in fasting states [121]. Even more interesting is the fact 
that Shc and PLC were found to only interact with IRS-2 
[121]. Recall that Shc ultimately activates the MAPK 
pathway, while PLC has more metabolic effects including 
GLUT4 translocation. IGF-1 displays more binding sites 
for SHP2 (a phosphatase related to growth) and seems 
more prone to recruit Cbl [121] (an E3 ligase that targets 
the receptor for ubiquitination and destruction) and thus 
may explain a different regulatory mechanism not medi-
ated by serine phosphorylation, and thus not so sensitive 
to metabolic derangements. Intriguingly, another inter-
esting research lead to the discovery of a differential role 
for IRSs in apoptosis, suggesting an antiapoptotic effect 
for IRS-2 [122] which is consistent with known differen-
tial roles of IGF-1 and insulin.
Taking all this data together it seems logical or appro-
priate to conclude that, because IGF1-R has a different 
signalling pathway that can maintain lipid oxidation in 
the liver, FFA uptake in muscle, and activates mTORC1 
could reactivate IR through tyrosine kinase activity on 
IRS, thus displacing serine phosphorylation, reinstitut-
ing insulin signalling. Also since most of serine inhibit-
ing phosphorylation occurs in IRS-1, it renders IGF-1R a 
rescue pathway to reinstitute insulin sensitivity. Because 
IGF-1 is normally found at low levels in MetS and T2D, 
maybe because of insulin cessation to inhibit IGFBP-1 
production by the liver and because of decreased 
liver IGF-1 secretion by insulin stimulation, as insulin 
resistance prevails in the liver. Consistent with the evi-
dence presented we suggest a positive effect towards re-
establishing IGF-1 levels by substitutive therapy only to 
physiological levels, never above them.
Insulin‑like growth factor‑1 metabolic effects
At a first glance, IGF-1 has historical fame for being a 
growth and differentiation factor, however, a number 
of growth-unrelated actions have been recently unrav-
elled [123]. From our perspective IGF-1, GH, and insu-
lin conform a finely regulated axis that inform cells about 
the nutritional status of the organism so that they can 
either undergo apoptosis/senescence/quiescence or, to 
the contrary, grow and differentiate. Parallel to this sig-
nal, potent protective effects have been attributed to this 
hormone, thus, besides signalling abundance and growth, 
it provides the protection against the possible deleteri-
ous effects of augmented metabolism. Likewise, anti-
inflammatory actions of IGF-1 [124] can be regarded as 
a crucial factor protecting tissues from the deleterious 
effects of pro-inflammatory mediators in chronic dis-
orders such as obesity. It has been well established that 
pro-inflammatory cytokines produced by the adipose 
tissue in obesity affect normal nutrition-related signal-
ling, establishing the progression to MetS and ultimately 
to T2D [125]. Additionally, it is now known that pro-
inflammatory cytokines also hijack IGF-1 intracellular 
signalling by phosphorylating serine residues on insulin 
related substrate (IRS) molecules and hence impeding 
their binding to IGF-1R [124]. This results in a blockade 
of IGF-1 beneficial actions [124, 126, 127]. Under this 
scenario, a correlation between IGF-1 and MetS can be 
established.
When caloric restriction is present, mammals synthe-
sise less IGF-1 and its synthesis in the liver is refractory 
to GH stimulation [128–130]. This process functions to 
limit growth and protein synthesis when nutrient avail-
ability is compromised. After a meal, GH responsive-
ness and IGF-1 synthesis is reinstituted [105, 106]. When 
inadequate carbohydrates are ingested, the decrease in 
portal vein insulin concentration leads to a reduction in 
IGF-1 synthesis by the liver [129, 131]. In pathophysio-
logical states, including increased insulin resistance, the 
hybrid receptor number is changed significantly, thus 
potentially abrogating the chance for IGF-1 to alter glu-
cose metabolism [129, 132, 133]. It is important to men-
tions that IGF-1 receptors are expressed ubiquitously 
[99]. This means that their actions can occur in all cell 
types, stimulating fat, carbohydrate, and protein meta-
bolic coordination, as we shall explain in detail herein. 
IGF-1 possesses both, GH-like actions and insulin-like 
actions, whose effects in  vivo depend on the dosage, 
length of treatment, and even route of administration 
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[134, 135]. However, GH can also exert metabolic actions 
independent from IGF-1 generation in the liver via acti-
vation of the phosphoinositide 3-kinase (PI3 K) and IRS 
pathways [98]. In this way, GH and insulin act in sym-
phony with IGF-1 to produce a coordinated response. 
Supported by an increasing number of studies these 
effects suggest the involvement of IGF-1 in metabolism 
coordination [136].
Insulin‑like growth factor‑1 and carbohydrate metabolism
IGF-1 can promote glucose uptake in certain peripheral 
tissues [137–140] in the magnitude of 4–7 % from that of 
insulin [141, 142]. In addition, exogenous IGF-1 admin-
istration has been shown to reduce serum glucose levels 
[95, 143, 144], not only in healthy individuals [140, 145–
147], but also in those with insulin resistance [148, 149], 
type I [150–152], and T2D [153–155]. An interesting 
experiment shows how, in the presence of insulin resist-
ance, there is up-regulation of the insulin/IGF-1 hybrid 
receptor expression in both, muscle and fat [133, 156]. It 
is important to bear in mind that IGF-1 serum concen-
tration is 100-fold greater than insulin, however when 
bound to IGFBPs its biological activity is modulated and 
in its free-unbound form presents different effects [99, 
157]. High doses of IGF-1 administration typically results 
in hypoglycaemia despite the potent suppression of cir-
culating insulin concentrations it triggers [134, 135, 158]. 
Even though this effect may be mediated by the insulin 
receptor, experimental KO mice for the insulin recep-
tor gene show a potent glucose lowering effect of IGF-1, 
indicative that the hypoglycaemic effect is also mediated, 
in part, by its own IGF-1R. However, this study was 
undertaken in 1–3 day old mice, as without IR they were 
not viable, and thus, results are not conclusive [159].
Berryman and colleagues revised IGF-1 actions on 
obesity, and concluded that this molecule possesses 
direct effects on muscle glucose uptake [160]. Moreover, 
KO mice for liver IGF-1 gene developed muscle insulin 
resistance (it is important to mention that skeletal mus-
cle myocytes express high number of IGF-1R), showing 
an increase in insulin concentrations and a substantial 
decrease in the insulin-induced autophosphorylation of 
the insulin receptor and IRS in skeletal muscle (being 
normal in liver and white adipose tissue). This effect was 
efficiently reverted by IGF-1 administration [161]. Such 
results could indicate that hepatic derived IGF-1 plays a 
crucial role in skeletal muscle insulin signalling and glu-
cose uptake. In murine studies, deletion of the IGF-1R in 
skeletal muscle resulted in glucose intolerance issues ulti-
mately leading to T2D at an early age, because, although 
they express insulin receptors, they cannot form hybrid 
or IGF-1 receptors [162]. When these mice where admin-
istered IGF-1 they showed lowered fasting glucose, and 
because no functional IGF-1R is present in muscle, such 
effect is believed to be due to renal gluconeogenesis sup-
pression [129, 163]. Our group, working with partially 
deficient IGF-1 mice, has demonstrated that the liver is 
capable of expressing IGF-1R (which under physiologi-
cal conditions it does not [99]) as a “defence” mecha-
nism (peer review). If the abovementioned is occurring, 
it could mean that IGF-1 administration could also lower 
glucose levels by suppressing hepatic gluconeogenesis, as 
well as improving insulin signalling in this organ, lead-
ing to IGFBP-1 suppression and overall improvement 
of the IGF-1/GH/insulin axis. Furthermore, additional 
performed studies suggested [164] that genetic expres-
sion of enzymes involved in glucose and lipid homeosta-
sis together with cholesterol transport are altered (as we 
shall further explain in detail later on).
IGF-1 reduces serum GH levels (via somatostatin nega-
tive feedback in the pituitary) which in turn suppresses 
GH actions in the liver, thus enhancing insulin actions in 
this organ [165]. In both, fat and liver, GH stimulates the 
synthesis of p85 subunit of PI3K [166] leading to the sup-
pression of p110 subunit activity and, thus, antagonising 
insulin’s actions [167]. Therefore, IGF-1 may indirectly 
modulate carbohydrate metabolism through GH sup-
pression and enhancement of insulin action.
During postprandial periods there is an increase in 
free circulating IGF-1 via insulin-induced suppres-
sion of IGFBP-1 secretion [168–170], which sequesters 
free IGF-1 making it unavailable. IGFBP-1 gene is tran-
scriptionally regulated by insulin in the liver [169]. This 
change in available IGF-1 may be (it is difficult to extrap-
olate data from altered IGF-1/GH concentrations from 
animal models, as each author measures IGF-1 levels 
using different methods) adequate for fatty acid (FA) oxi-
dation in muscle, suppression of GH, stimulation of glu-
cose transport into muscle [171, 172], and lastly for the 
suppression of renal gluconeogenesis in mice [163].
Besides the already discussed actions of IGF-1 on glu-
cose, it also has an indirect glucose-lowering effect sec-
ondary to its ability in increasing FA oxidation in muscle 
(will be further discussed in detail within the IGF-1 
and lipid metabolism section). Such ability produces a 
decreased FFA flux in the liver and hence insulin signal-
ling is improved, being now able, such signalling to sup-
press hepatic glucose output [166].
IGFBPs are also hypothesised to play a role in glucose 
metabolism. IGFBP-1 regulates glucose levels through 
its effect on free IGF-1. IGFBP-2 actions are linked to 
insulin, although only in cases of hyperinsulinemia [173] 
where it seems to play a role on adipocyte autocrine con-
trol [174]. It has been reported that IGFBP-3 binds to a 
nuclear receptor, 9-cis retinoic acid receptor-alpha (RXR-
α), which interacts with peroxisome proliferator activated 
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receptor-gamma (PPAR-γ), a nuclear protein involved in 
the regulation of glucose and lipid metabolism [175, 176]. 
A transgenic mice study stated that the overexpression of 
IGFBP-3 is associated with impaired glucose tolerance 
[177, 178]. Also, IGFBPrPs have been associated with 
insulin resistance and fasting glucose levels [179, 180].
In a recent investigation undertaken by our group, 
adult mice with partial IGF-1 showed a decrease in the 
expression of genes involved in glucose metabolism 
(phosphoenolpyruvate carboxylase-1, glucose-6-phos-
phatase, pyruvate dehydrogenase kinase isoenzyme-4, 
and ATP-citrate lyase), resulting serious hyperglycae-
mia [164]. Such genetic alterations were all reverted by 
low doses if IGF-1 replacement therapy for only 10 days. 
Interestingly, it is well accepted that insulin increases 
the expression of glucose-6-phosphatase and phospho-
enolpyruvate carboxylase-1. Results in the study demon-
strate that IGF-1 induces the opposite effects since the 
IGF-1 deficit reduces the expression of glucose-6-phos-
phatase and phosphoenolpyruvate carboxylase-1. Thus, 
these activities of IGF-1 are not “insulin-like” but rather 
antagonistic. These findings reinforce the role of IGF-1 
in glucose homeostasis. Also, pyruvate dehydrogenase 
kinase isoenzyme-4 encodes pyruvate dehydrogenase 
complex (PDK). PDK is an emerging target for the treat-
ment of MetS which may allow the maintenance of the 
steady-state concentration of adenosine triphosphate 
during the feed-fast cycle. For that, cells require efficient 
utilization of fatty acids and glucose, and such is con-
trolled by PDK. Particularly the pyruvate dehydrogenase 
kinase isoenzyme-4 gene encodes PDK that converts 
pyruvate, CoA and oxidized nicotinamide adenine dinu-
cleotide (NAD+) into acetyl-CoA, the reduced form of 
nicotinamide adenine dinucleotide (NADH) and carbon 
dioxide.
Insulin‑like growth factor‑1 and lipid metabolism
IGF-1 promotes preadipocyte differentiation [181], how-
ever, as preadipocytes differentiate, they stop express-
ing IGF-1Rs, delegating such functions now to insulin 
receptors, which increase in number significantly. Thus, 
in the adipose tissue, physiological IGF-1 concentrations 
are not effective in stimulating changes in lipid synthe-
sis or lipolysis, only at high concentrations is capable of 
stimulating glucose transport via the insulin receptor 
[182]. Contrarily, a study with 8 GH-deficient subjects 
found that IGF-1 administration increased lipid oxida-
tion (being this effect more potent when co-administered 
with GH), energy expenditure, and insulin resistance 
[108, 183]. This effect is believed to be due to IGF-1 sup-
pression of insulin secretion, which leads to augmented 
lipolysis in adipose tissue and promotion of FFA use by 
muscle.
Although mature adipocytes are not a target for IGF-1, 
they secrete it. In fact, cultured adipocytes secrete more 
IGF-2 than IGF-1, and predominantly IGFBP-4. Growth 
hormone, interleukin-β (IL-1β), and TNF-α affect secre-
tion of IGF-1—whereas IGF-2 is affected by TNF-α only. 
Hence, cytokines may control adipocytes homeostasis by 
affecting local IGF-1 synthesis [160].
Growth hormone has direct effects on mature adi-
pocytes that result in the release of FFAs following TG 
breakdown and in increased FFA oxidation in the liver 
[182]. GH can enhance the lipolytic effect of catechola-
mines by increasing the number of adrenergic receptors 
in adipocytes. GH also increases hepatic glucose produc-
tion [184, 185] and leads to increased lipolysis in adi-
pocytes through the β-3 adrenergic receptor [185, 186]. 
Such receptor activates the protein kinase A (PKA) cas-
cade, eventually activating lipases [185, 187, 188]. Addi-
tional effects include uncoupling of the electron transport 
chain to produce heat [185, 189]. In skeletal muscle, GH 
increases lipoprotein lipase activity via the β-3 adrenergic 
receptor, as a result facilitating FFA use [186].
On the other hand, insulin is a potent stimulant of lipid 
synthesis, antagonising TG breakdown. An increase in 
FFA efflux from adipose tissue to liver can result in insu-
lin resistance in the liver and GH is known to antagonise 
insulin action by this mean [183]. Definitive evidence of 
the role of FFAs in GH-mediated insulin resistance was 
obtained in clinical studies in which the effects of exog-
enously administered GH on insulin resistance were 
abrogated by Acipimox™—an inhibitor of lipolysis [185, 
190, 191]. The increased efflux of FFAs from adipose tis-
sue to lipid-sensitive tissues (such as liver and skeletal 
and cardiac muscle) increases serine phosphorylation 
of IRSs. Such phosphorylation leads to the blockade of 
the tyrosine residues in IRSs, to which the insulin and 
IGF-1 receptors phosphorylate to activate IRSs and con-
sequently commence the signalling cascade [185, 192], as 
comprehensively discussed above.
IGF-1 promotes fatty acid transport in muscle [162, 
183, 193] and its inhibition causes severe consequences 
like insulin resistance and eventual diabetes [162]. This 
is due to the liver taking up all the circulating FFAs, 
which then interfere with insulin and IGF-1 signalling 
(as described above) and eventually leading to hepatic 
steatosis. Therefore, the two major effects that are 
enhanced by IGF-1 are FFA use by muscle and GH sup-
pression. These two actions result in a decreased FFA 
flux in the liver, improving insulin and IGF-1 signalling. 
Such improvement promotes lipogenesis in fat (recall 
that IGF-1 could maintain cytokine homeostasis—anti-
inflammatory effects-, and thus protection from mild 
inflammation as a consequence of obesity). This fact, 
linked to the augmented FFA use by muscle and insulin 
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signal reinstitution by IGF-1, results in a marked reduc-
tion in total FFA flux.
Moreover, IGF-1 could be implicated in nutrient 
absorption as our group demonstrated more than a dec-
ade ago. We showed that cirrhotic (an IGF-1 deficiency 
condition) rats had diminished amino acid and glucose 
intestinal absorption [114, 194, 195] and that IGF-1 
replacement therapy was able to restore both alterations, 
suggesting a role of IGF-1 in the position of transport-
ers [196]. Such findings suggest that IGF-1 implications 
on metabolism may not only affect energy use and bal-
ance, but as well act regulating transport and nutrient 
absorption. Therefore, this finding could be indicating 
that IGF-1 deficiency could be altering nutritional bal-
ance. However, more profound studies in the matter are 
necessary.
In the aforementioned study from our group, adult 
mice with partial IGF-1 also displayed decreased expres-
sion of genes involved in lipid metabolism (ATP-citrate 
lyase, acetyl-CoA acyltransferase 1B, acetyl-CoA acetyl-
transferase 1) and cholesterol synthesis and transport 
(Both HMG-CoA reductase and synthase, LDL-related 
protein 1, proprotein convertase subtilisin/Kesin type 9), 
resulting in dyslipidaemia. Such genetic alterations were 
reverted by IGF-1 replacement therapy and may seriously 
contribute to the establishment of MetS [164].
Figure  1 and Table  2 have been included to represent 
schematically IGF-1 actions in metabolism with target 
organs.
Can insulin‑like growth factor‑1 deficiency be 
involved in metabolic syndrome establishment?
An assortment of epidemiological and clinical studies 
have stated glucose and lipid metabolism alterations, 
insulin resistance, and central obesity as predominant 
factors for the development of MetS [38, 212].
Similarities between insulin and IGF-1 suggest the 
possible role of IGF-1 in the pathological process of this 
syndrome, therefore several studies have attempted to 
correlate IGF-1 plasma levels with MetS. Figure 2 repre-
sents the pathophysiology of an altered IGF-1/GH/insu-
lin axis, and potential beneficial actions of IGF-1 therapy.
A general finding is that obese patients fulfilling crite-
ria for MetS together with low IGF-1 plasma levels tend 
to develop a worse cardiovascular disease outcome than 
those with mid-normal to high-normal IGF-1 levels 
[213]. Nevertheless, many of them also present insulin 
resistance and inflammatory cytokine secretion, so it is 
difficult to determine the exact role of each component in 
the cardiovascular outcome.
Nonetheless, low IGF-1 circulating levels are also asso-
ciated with reduced insulin sensitivity [207], glucose 
intolerance, and T2D [207, 208, 214]. Moreover, some 
inflammatory cytokines are known to reduce IGF-1 levels 
in animal models [215]. Additionally, the IGF-1/IGFBP-3 
ratio, a common rough of free IGF-1 levels, is signifi-
cantly decreased in obesity [216], however no IGF-1 
bioactivity was estimated. This parameter has been fur-
ther studied, showing that those men and women in the 
lowest quartile of the IGF-1/IGFBP3 ratio are threefold 
more likely to meet the Adult Treatment Panel III (ATP-
III) definition for MetS, and twice as likely to be insulin 
resistant—that IGF-1/IGFBP-3 ratio decreases notably 
as the number of MetS components increases [217]. Fur-
thermore, visceral adipose tissue mass has been inversely 
correlated with circulating IGF-1 levels [216]. Neverthe-
less, the mechanism of this possible inverse relationship 
between MetS and free IGF-1 levels remains unclear.
A very interesting epidemiological study that supports 
this idea showed that in normal subjects, IGF-1 contrib-
utes to glucose homeostasis. This study analysed a group 
of Dutch Caucasians with a polymorphism in the pro-
moter of the IGF-1 gene [129, 218]. Results within this 
group showed a reduced IGF-1 secretion—40  % lower 
than those without the polymorphism. These subjects are 
2.1 cm shorter and have 2.2-fold increase in T2D preva-
lence after the age of 60 [129, 219]. A different study [220] 
tested IGF-1 in response to energy intake in the Gujarati 
migrant community in Sandwell (UK) and data was com-
pared with people still resident in their village of origin in 
India. Total energy and total fat intake were higher in UK 
migrants, as were IGFBP-3 and IGF-1, but IGFBP-1 was 
lower in UK migrants. At both sites, IGF-1 and IGFBP-3 
correlated positively with total energy and fat. Con-
versely, in Indian Gujaratis, IGFBP-1 fell with increasing 
total energy and fat intake but not in UK Gujaratis.
Several other studies (one of them being a large scale 
community-based Framingham Heart Study [221]) have 
suggested a role for IGF-1 in the prevalence of insulin 
resistance and MetS [221–223]. Biomarkers correlating 
the lower IGF-1 concentration to increased waist-to-hip 
ratio or to impaired glucose tolerance are also being stud-
ied [224, 225].
Insulin-like growth factor-1, as discussed earlier, has 
implications on lipid and glucose metabolism [87, 88], 
and its exogenous administration enhances insulin sen-
sitivity in healthy adults [139, 140] as well as those with 
T2D [155].
A fascinating study including over 500 patients 
revealed that IGF-1 concentrations were independently 
associated with insulin sensitivity accounting for 10.8 % 
of its variation. The results were assessed by HOMA-
S together with anthropometric measurements, HDL, 
TG and blood pressure, and found correlations between 
these parameters and IGF-1 plasma levels. Additionally, 
they established that according to the WHO definition 
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for MetS, each unit increase in log-transformed IGF-1 
concentrations, was associated with a 90.5 % reduction in 
the risk of MetS [226].
Salmon et  al. [227] showed that transgenic mice with 
reduced levels of IGF-1 can induce female insulin resist-
ance [227]. Moreover, global deletion of IGF-1 gene 
expression in mice does not result in glucose intolerance. 
It has to be mentioned that KO mice for IGF-1 gene are 
not viable and studies in such mice have to be done in the 
first days of life, and thus results are not very conclusive 
as metabolism is not properly established at this stage 
[129, 228]. However, if a partial deletion is present, the 
mice will develop glucose intolerance if starved. Addi-
tional studies found that elimination of hepatic IGF-1 
gene expression results in a compensatory threefold 
increase in GH secretion—recall that IGF-1 is secreted 
by GH stimulation in hepatocytes. This combination of 
lowered serum IGF-1 and increased GH secretion leads 
to increased insulin resistance—as in the systemic dele-
tion but also developed glucose intolerance [129, 209]. 
Interestingly, glucose intolerance could be improved 
when IGF-1 was systemically administered. This response 
was caused primarily by GH hypersecretion, as expres-
sion of a GH antagonist resulted in improvement of glu-
cose homeostasis [129, 229]. Additionally, administration 
of IGF-1 in the presence of this antagonist results in a 
further improvement in insulin sensitivity; suggesting 
that, at high concentrations, IGF-1 has effects not sim-
ply mediated by suppressing the effect of GH on hepatic 
insulin sensitivity [129, 209]. In a similar study, the piv-
otal role for the IGF-1 in insulin sensitivity has received 
further support from liver-specific IGF-1 KO mice which 
exhibited overt insulin resistance and hyperinsulinaemia 
that was reversed by the administration of IGF-1 [161].
 Lipolysis179, 186 IGF-1 Synthesis98-100 
 Gluconeogenesis132,134
 FFAs Uptake & Oxidation 
160, 175, 216 
 Glucose Uptake120, 126, 129
FFAs
 IRS Phosphorylation
(Insulin Resistance & 
IGF-1 Signalling)180, 186
 IGF-1 Synthesis123-125, 222-223 
 IGFBP-1 Synthesis164(  Free IGF-1) 








 Somatostatin GHRH 89-91
 GH Synthesis
Fig. 1 Metabolic effects of IGF‑1, GH, and insulin under physiological conditions on their target organs. The figure summarises schematically some 
of the metabolic effects that IGF‑1 (blue continuous line), GH (red discontinuous line), and insulin (green dotted line) exert on kidney (upper left), brain 
(upper centre), skeletal muscle (left), liver (centre), adipose tissue (right), and pancreas (bottom). GH growth hormone, GHRH growth hormone releas‑
ing hormone, FFA free fatty acid, IRS insulin receptor substrate, IGF-1 insulin‑like growth factor 1, IGBBP-1 insulin‑like growth factor binding protein 1
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Moreover, results from the aforementioned Framing-
ham heart study also demonstrated the correlation 
between low IGF-1 and the increasing metabolic syn-
drome markers [221]. A good example is the finding that 
low circulating levels of IGF-1 are independently associ-
ated with hyperglycaemia and insulin resistance in adults 
[160, 230–232]. To the contrary, high to normal levels of 
circulating IGF-1 correlate with a rise in adiponectin lev-
els and a reduced prevalence of MetS is found [233].
Since the liver is the major site of IGF-1 production, 
when steatosis develops lowering insulin sensitivity, the 
severity of steatosis at different stages of insulin resist-
ance and metabolic syndrome seems to be correlated 
with worsened circulating IGF-1 levels [234]. In addi-
tion, low IGF-1 subjects in a study were found to possess 
up-regulated fatty acid metabolism along with down-
regulated GLUT-1 gene (in charge of glucose uptake in 
erythrocytes, brain endothelial cells, eye, peripheral 
nerve and also responsible for materno-placental glucose 
transfer) [210].
In summary, reconciling all discussed aspects rel-
evant to insulin, IGF-1 improves insulin sensitivity by 
suppressing insulin and GH secretion and by improving 
insulin signalling indirectly reducing FFA flux.
When we look to IGF-1 levels in sera from T2D 
patients, the results found are very wide [235]. It must be 
considered that multiple factors interact to control IGF-1 
levels, many of which are disturbed in T2D, namely: 
increased inflammatory cytokines, decreased hepatic 
insulin action due to resistance, concomitant changes 
in IGFBPs, and the effects of obesity. In addition, T2D 
is the result of a complex interaction of environmental 
and genetic factors, being difficult to establish the role of 
each one in the pathogenesis of diabetes and in the lev-
els of IGF-1. In an experimental model, transgenic mice 
expressing a kinase-deficient IGF-1R β-subunit (thus 
displaying reduced signal transduction in both IGF-1R 
and hybrid receptors) developed diabetes early on life 
[162, 236]. Also, mice carrying a genetic mutation that 
lack one of the igf1r alleles (igf1r+/−) show a 10 % reduc-
tion in post-natal growth, insulin resistance and glucose 
intolerance [237]. Additionally, infants born small for 
gestational age who exhibit low IGF-1 levels presented 
a higher risk for the onset and development of T2D in 
ROS Production
Fig. 2 Metabolic effects of IGF‑1 and GH under pathological conditions. The figure summarises schematically some of the metabolic mechanisms 
altered in obesity and the role that IGF‑1 and GH exert on them
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adult life than those born with normal weight [238, 239]. 
Nevertheless, it is noteworthy that the inverse correla-
tion between IGF-1 and diabetes only prevails in younger 
individuals (<65  years) [231], establishing that this defi-
ciency can lead to MetS—as aging can be considered an 
IGF-1 deficiency condition [107].
Abnormal IGF-1 and GH levels have been proposed to 
play a key role in obesity [130, 240, 241]. Obese human 
and animal models are generally accompanied with 
abnormal circulating IGF-1 levels [130], as well as IGF-1/
IGFBP-3 ratio; and an inverse relationship between IGF-1 
and visceral fat mass distribution has been described 
[242–246] as previously mentioned.
Moreover, some studies revealed that high fat diet pro-
moted reactive oxygen species (ROS) and cytokine pro-
duction, apoptosis, protein and mitochondrial damage, 
and reduced ATP content. These defects were accom-
panied by disrupted phosphorylation of the IRS, as well 
as down-regulated expression of mitochondrial proteins 
PPARγ co-activator 1α (PGC1α) and uncoupling pro-
tein-2 (UCP-2) [200]. All of these factors can be allevi-
ated by the cytoprotective and anti-inflammatory actions 
of IGF-1 [105, 123, 247–249].
The culmination of all of these studies come to light 
with the finding of several (some reported and many 
from our group still publication pending) Laron’s Syn-
drome (congenital IGF-1 deficiency or GH insensitivity) 
never treated patients who underwent progression to 
MetS and ultimately to T2D together with diabetic retin-
opathy when they reached their late 30 s, [250, 251].
The role of insulin‑like growth factor binding proteins 
in metabolic syndrome
Recall that IGFBPs have a very important role, not only in 
modulating free IGF-1, half-life and localisation, but also 
by possessing IGF-independent activities mediated by 
their own receptors. Changes in IGFBPs have been corre-
lated with certain parameters of MetS. For instance, low 
IGFBP-1 levels with high C-reactive protein values are 
strong predictors of MetS [252, 253]. Low IGFBP-2 also 
acts as a good marker for MetS along with high fasting 
glucose [254]. Even though the data is extensive it is not 
enough to explain any relationship between these mol-
ecules and the independent MetS factors, or any mecha-
nism by which these molecules could be involved in the 
pathophysiology.
As a result of IGF-1 changes, IGFBPs are also altered in 
T2D [255]. Studies in prediabetes suggest that IGFBP-1 
shows normal levels before developing T2D [256]. This 
may be caused by hyperinsulinaemia during the onset 
of the disease. Elevated insulin causes an increase of free 
serum IGF-1, nevertheless, as resistance to insulin pro-
gresses, the liver becomes insensitive to insulin-mediated 
suppression of IGFBP-1 [254, 256]. On the other hand, 
IGFBP-3 undergoes augmented proteolysis on diabetic 
patients which results in a sudden rise of free IGF-1 con-
centrations [257, 258].
Overexpressed IGFBP-1 in transgenic mice shows that 
its increase produces hyperinsulinaemia accompanied by 
glucose intolerance, and that this process is dependent 
upon IGFBP-1 phosphorylation state—which is increased 
in diabetes [259]. In another study it was found that after 
weight loss there is a rise in IGFBP-1 and IGFBP-2, both 
in children and adults [260, 261]. Considering that IGF-1 
regulates IGFBP-1 and IGFBP-2, it is reasonable to con-
clude that early changes in insulin resistance alter their 
concentrations.
A recent study tested whether IGFBP-1 concentrations 
were able to predict the development of T2D in women. 
The outcomes showed that women with the lowest fast-
ing IGFBP-1 at baseline had a higher risk for develop-
ing diabetes within 8  years, also showing an impaired 
IGFBP-1 suppression after oral glucose loading [256]. 
Conversely, in another study, 615 patients with IGF-1 
values in the lower half of the normal range were closely 
observed during 4.5  years. It was found that there was 
an increased predisposition to develop glucose intoler-
ance or T2D, and that this change was independent from 
IGFBP-1 [208].
Moreover, IGFBP-2 is decreased in obese patients and 
thus increasing free IGF-1 [262]. This fact is relevant as 
transgenic mice overexpressing IGFBP-2 were resistant 
to developing obesity when fed with high fat diet [174], 
suggesting that this molecule could have a direct effect 
on preadipocyte differentiation.
IGF‑1 treatment: future and limitations
The FDA approved the use of rhIGF-1 (Mecasermin, 
Increlex™) for treatment of severe primary IGF-1 defi-
ciency in 2003. By the same time, the FDA approved the 
use of a equimolar combination of IGF-1 and IGFBP-3 
(Mecasermin Rinfabate, iPlex™), suggesting that it would 
be a better choice, seeming as it will require lower doses 
because of the augmented half-life of the molecule and 
“buffering” effect on concentration. Additionally this 
complex can bypass the IGF-2 displacement effect. 
Because IGFBP-3 also carries IGF-1, when IGF-1 is 
administered on its own, the carrier IGFBP-3 saturates 
with IGF-1 displacing IGF-2 and thus augments its free 
circulating concentration. However, subsequent studies 
revealed that no significant difference (among with some 
patient issues) could be observed, so now IGF-1 alone 
seems to be an efficient treatment. Recombinant human 
IGF-1 is usually synthesised in E. coli and subsequently 
purified. Its purification is a very insidious process that 
elevates the cost, and this fact in combination to the 
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limited applicability that has been linked to date, elevates 
the price of the treatment.
The use of analogues has shown multiple and substan-
tial clinical benefits along with metabolic improvement. 
A promising therapeutic approach being studied uses 
IGF-1 analogues such as PEG-IGF-1 [263], which offers 
promising protection against acute contraction-induced 
muscle injury.
To date several clinical trials have been conducted to 
test IGF-1 under several conditions and an infinity of ani-
mal models have been used to investigate its deficiency, 
treatment and to exploit its actions. Phase I studies from 
the late 1980s using IGF-1 to treat Laron’s Syndrome (GH 
insensitivity) revealed effective increase in linear growth 
reaching adult heights using doses ranging from 80 to 
240  µg/kg/day [264–268]. Different groups of patients 
and candidates for IGF-1 treatment have been those with 
an IGF-1 gene deletion and others with idiopathic short 
stature. Furthermore, phase II studies were undertaken 
to prove the efficacy of mecasermin rinfabate (IGF-1/
IGFBP-3) in paediatric severe burns and had promising 
outcomes when doses of 1–4 mg/kg/day [269–273] were 
used. Moreover IGF-1 was tested in patients with osteo-
penia/osteoporosis linked to anorexia nervosa and severe 
bone fractures with positive results utilising doses rang-
ing from 30 µg to 1 mg/kg/day for 2–9 months [274, 275].
When treating metabolic disorders with IGF-1, phase 
II trials until now conducted by Clemmons et al. includ-
ing adult patients with either T1D or T2D treating with 
mecasermin rinfabate (1–2  mg/kg/day for 14  days) 
showed lowered exogenous insulin requirements while 
improving glycaemic control. These results suggest 
improvement in insulin sensitivity, and moreover, no 
additional side effects to those found with placebo were 
observed in T1D, meanwhile in T2D patients oedema, 
jaw pain and arthralgias were 4  % lower than previous 
reports [276, 277]. Evidence revealed that endogenous 
and exogenous IGF-1 administration protects against the 
onset and progression of diabetic cardiomyopathy [278, 
279]. Consistent with this, patients with T2D responded 
to IGF-1 treatment with improved glucose tolerance, 
hyperinsulinaemia, and hyperlipidaemia as previously 
stated [280]. Up to date, limited information is available 
regarding obesity treatment by regulation of the GH-
IGF-1 system. Apart from all of these conditions tested 
under IGF-1 treatment, there are a number of other ones, 
among others: cystic fibrosis, AIDS, Chron’s, multiple 
sclerosis and ALS—which are carefully revised by Rosen-
bloom [281].
Despite all the above-mentioned clinical benefits, 
the safety of long-term administration of this hor-
mone remains controversial. There is supporting evi-
dence reporting adverse effects from long-term rhIGF-1 
treatment including neoplastic formation, cataract and 
renal hypertrophy, all of which seem to be the most 
severe effects observed and are usually rare [123, 282–
284]. Additionally these complications were transient, 
easily treated and tolerated without treatment discon-
tinuation. More common side effects within the men-
tioned studies revealed mild to moderate effects like 
pain at site of injection or headache that was transient 
and disappeared after 1 month [268]. Other side effects 
reported ranged from lipohypertrophy at injection site, 
papilloedema (related to cranial hypertension), and facial 
nerve paralysis [276, 285], however symptoms did not 
prevail after treatment pause and restarting with lower 
doses [268]. The usual concern with regards to treatment 
with IGF-1 has historically been hypoglycaemia, however 
in the trials done so far it has not always occurred and 
had been lessened when administered with meals—it was 
also usually connected to an appearance in a loss of appe-
tite [264, 286]. Another reported effect has been growth 
of lymphoid tissue (specially acromegaly and tonsillar 
hypertrophy), renal enlargement (with normal kidney 
function) and in rare cases facial coarsening of features 
and incremented hair growth [264].
Of further importance is the well-known effect of exer-
cise in IGF-1 plasma level rise. It has been determined 
for years that after only single bouts of moderate to high-
intensity total IGF-1 plasma levels rise up to ∼10–30 % 
and peak only after 5–10 min after the onset of the train-
ing [287]. This rapid increase has been argued to be due 
either to a release of IGF-1 stores in tissues or due to a 
proteolytic cleavage of IGFBP-3 either in the plasma or 
in tissue. Also it must be noted that during exercise pH 
drops dramatically and this affects negatively to IGFBPs 
affinity for IGF-1/2. It has been somehow elucidated that 
muscle tissue is the one movilising most of the IGF-1 
from cells to plasma [288]. This muscle autocrine/par-
acrine/endocrine effect has various effects. Apart from 
the obvious differentiation of satellite cells, which may 
account for many of the beneficial actions of exercise 
training, without excluding the classical fat burning, 
cardiovascular tonification, neuroendocrine system acti-
vation and chronic inflammation grade lowering. These 
actions have been reviewed herein, but of special men-
tion during exercise is the recruitment of hippocampal 
neuroprogenitor cells and improved neuroglia function 
[289, 290]. Moreover, it has been recently proven that 
IGF-1 central administration also induced improve-
ment in insulin sensitivity [291], meaning that this sud-
den rise after exercise or treatment could be of benefit 
not only in the periphery, but acting centrally. It must be 
reminded that in our experience, IGF-1 treatment does 
not only raise IGF-1 plasma levels, but also stimulates 
tissues to synthesise their own IGF-1 by a mechanism 
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still not uncovered, aiming these mechanisms of central 
stimulation of peripheral improvement. These facts are 
in accordance with the perspective of this review which 
suggests the central and nuclear role of IGF-1 in metabo-
lism. Because exercise is the current best option when it 
comes to restore metabolism and obesity inflammation 
problems (i.e. for MetS and T2D), and because exercise 
is one of the most potent IGF-1 synthesis/freeing mech-
anisms, it seems logical to correlate them and establish 
IGF-1 as a target for future options in the multifactorial 
treatment for metabolic syndrome.
Inasmuch, these complications have caused fear and 
controversy among studies and opinions towards the 
safety of the treatment even when there are findings sup-
porting the need for further investigation in the field of 
metabolic disorders. In our experience, and the problem 
we often see in these trials, comes to the dosage admin-
istered which are brutally over the target of restoring the 
physiological normal levels of the hormone. All studies 
have been conducted using 80 µg–4 mg/kg/day and rang-
ing in a wide spectrum of lengths (weeks to months) and 
routes of administration. In all our previous murine stud-
ies we have used short cycles (10–14  days) of very low 
subcutaneal doses (20  µg/kg/day) after carefully assess-
ing its circulating concentrations and using the mini-
mum amount that was sufficient to adequately restore 
physiological values of the molecule. Using these con-
centration we have not yet perceived any of the reported 
adverse affects, including hypoglycaemias, retinopathies 
or any others. We are conscious of the limitations of the 
animal models [123], however in a clinical trial under-
taken by this group to asses IGF-1 in liver function under 
cirrhosis with these same dosage (20 µg/kg/day) no side 
effects were reported and liver function greatly increased 
[108]. So, as this group has been experimenting over the 
last years, the problem with IGF-1 is a matter of dosage. 
Even more intriguing is the fact that none of the inclusion 
criteria for the above-mentioned studies encompassed 
tumour markers to potentially discard any ongoing or 
potential tumour process that, obviously, IGF-1 could 
accelerate. IGF-1, as happens with other hormone ther-
apies (thyroid hormone or insulin), should never been 
used lightly without firstly assessing its deficiency (local, 
central or systemic) and secondly by ascertaining that no 
tumours are near to be generated. Careful monitoring 
during treatment should be carried out to guarantee a 
safe outcome.
Conclusions
It can be plainly concluded that everyday more IGF-1 
roles are being unravelled which concern energy metabo-
lism. In the present review we have summarised how the 
GH/IGF-1 axis, together with insulin and IGFBPs act in 
a coordinated manner to regulate energy flux and use. 
From our point of view, when this whole system becomes 
altered-whether obesity, genetics or environmental fac-
tors act to disrupt its symphony-insulin resistance, stea-
tosis, MetS, and ultimately T2D may develop. In our 
experience and from the information presented in this 
review, IGF-1 acts as the cornerstone maintaining home-
ostasis in this system.
In the last decade several studies have been conducted 
which revealed the relevant role of IGF-1 in the devel-
opment of MetS. Briefly, an inverse correlation between 
IGF-1 (IGF-1/IGFBP-3 ratio) circulating levels and sev-
eral markers for obesity, MetS, T2D, and CVD has been 
found; and thus, it could indicate that low circulating 
levels of IGF-1 can lead to MetS and raise the risk for 
CVD and T2D. Nevertheless, more studies are needed to 
describe the exact mechanism by which IGF-1 impacts 
and interacts with other factors and hormones in order 
to develop each component of MetS, T2D and its cardio-
vascular consequences.
The axis GH/IGF-I is claiming a particular physiologi-
cal understanding. Usually IGF-1 deficiency is associated 
to “GH resistance” or “GH insensibility” states. IGF-1 
replacement therapy induced a restoration of the altered 
GH/IGF-1 axis by reducing circulating GH levels and 
recovering the somatostatinergic tone [292].
Low doses of IGF-1 seem to be able to restore circu-
lating levels of this hormone promoting beneficial effects 
without undesired side effects (including hypoglycaemia). 
Secondary effects from IGF-1 therapy were reported after 
administration of doses higher than 60–80 μg/kg/day.
In summary, the implication of IGF-1 in glucose and 
lipid metabolism and its derangements when the GH/
insulin/IGF-1 axis balance fails is well documented. IGF/
IGFBPs level alterations in MetS have been, to some 
extent, observed, however the exact mechanism has not 
been elucidated—still it suggests a trend towards IGF-1 
local or systemic deficiency or availability. It is still too 
early to consider IGF-1 as the key factor; rather, literature 
is providing the clue suggesting that it is a good endeav-
our to pursue in order to achieve an appropriate phar-
macological target that could aim at reversing MetS in 
parallel with diet and exercise before it onsets T2D. This 
group only suggests such treatment when IGF-1 defi-
ciency prevails, acting merely as a substitutive therapy, 
and never to exploit its multiple actions. Diet and exer-
cise must be considered as the first line of “treatment”, 
however if they fail to correct metabolic signalling, IGF-1 
therapy seems to be promising at metabolic harmonisa-
tion. For this to become a fact, however, further carbon 
tracer, protein and gene expression studies, together with 
large patient protocols are needed to reveal the exact role 
of IGF-1 in the whole system; meaning, to establish a way 
Page 16 of 23Aguirre et al. J Transl Med  (2016) 14:3 
to direct IGF-1 supplementation towards exactly where 
it is needed in order to avoid MetS from progressing to 
more grave outcomes.
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